A Study to Evaluate Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Overview

About this study

The purpose of this study is to evaluate how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Current cancer diagnosis, about to receive oral everolimus 10 mg/day with or without an endocrine agent.
  • Patients about to receive everolimus for off label use for any cancer are also eligible. 
  • Not currently receiving chemotherapy or any other agent known to cause mucositis or stomatitis.
    • Trastuzumab and ovarian function suppression are allowed. 
  • Any prior chemotherapy or other stomatitis/mucositis-causing therapy must be completed at least 2 weeks prior to registration. 
  • Not currently suffering from stomatitis/mucositis or mouth ulcers.
  • Patients should not have had any stomatitis or mouth pain for at least 7 days prior to registration. 
  • Patients should not receive any other agent which would be considered treatment for stomatitis or impact the primary endpoint. 
  • No history of candida infection (thrush) within the last 3 months. 
  • Not currently being treated with corticosteroids.
  • No uncontrolled diabetes mellitus, defined by hemoglobin A1C greater than 8%; although A1C is not needed for all patients, hemoglobin (Hgb)A1C < 8 is required for everyone with diabetes or suspected diabetes. 
  • Patients must be able to read and comprehend English.
    • Local translation, including verbal translation of professionals (PROs) is not permitted.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
  • Women of childbearing potential only:
    • A negative pregnancy test done ≤ 7 days prior to registration. 

Exclusion Criteria:

  • Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kathryn Ruddy, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

La Crosse, Wis.

Mayo Clinic principal investigator

Kathryn Ruddy, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Eau Claire, Wis.

Mayo Clinic principal investigator

Kathryn Ruddy, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20463723

Mayo Clinic Footer